▸ We could be required to collect additional sales, value added or similar taxes or be subject to other tax liabilities that may increase the costs our clients would have to pay for our products and adversely affect our results of operations.· · · ● 1 ▸ We are currently operating in a period of economic uncertainty, which has been significantly impacted by geopolitical instability, inflation, increases in interest rates, and other disruptions in credit and financial markets.· · ● ● 2 rw ▸ A third party may hold intellectual property, including patent rights that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of a third party to· · ● · 1 ▸ As of December 31, 2024, we had 23 full-time employees. As our development and commercialization plans and strategies develop, we will need additional managerial, operational, sales, marketing, scientific and financial headcount and other· · ● · 1 ▸ Since inception, we have dedicated a majority of our resources to the discovery and development and marketing of our proprietary product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable· · ● · 1 ▸ We continue to develop a functional infrastructure for the sales, marketing and distribution of our products; however, the cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness of doing so. In order to· · ● · 1 ▸ If we are unable to establish and maintain an effective sales force and marketing and distribution infrastructures, or enter into and rely upon acceptable third-party relationships, we may be unable to generate any revenue.· ● ● · 2 ▸ ContraPest and our other product candidates, if approved, may not achieve adequate market acceptance necessary for commercial success.● · · · 1 ▸ Even following receipt of any regulatory approval for ContraPest and our other product candidates, we will continue to face extensive regulatory requirements and our products may face future development and regulatory difficulties.● · · · 1 ▸ Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of the shares and dilute stockholders.● ● ● · 3 ▸ If we are unable to continue as a going concern, our securities will have little or no value.● ● ● · 3 ▸ If we raise additional funds through collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue● · · · 1 ▸ Our future success may also be dependent on regulatory approval and commercialization of other product candidates.● · · · 1 ▸ Our reverse stock splits may decrease the liquidity of the shares of our common stock.● ● ● · 3 ▸ Regulatory approval processes of the EPA and comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may fail.● ● ● · 3 ▸ The coronavirus pandemic may continue to adversely affect our business, and other similar public health crises could result in similar or other harms.● · · · 1 ▸ We are actively working on a semi-solid product and a product to control fertility in mice. We cannot commercialize our product candidates in the United States without first obtaining regulatory approval for each product and each use pattern● · · · 1 ▸ We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing Russia-Ukraine and Israel-Hamas wars.● ● · · 2 rw ▸ We are dependent on triptolide, a key ingredient for ContraPest, which has limited sources and must be in a very refined condition.● ● ● · 3 ▸ We are making sales through our new e-Commerce tool, which depends on information technology systems and networks. We are also responsible for storing data relating to our customers and employees and rely on third party vendors for the● ● · · 2 ▸ Business or supply chain disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.● · · ● 2 rw ▸ A variety of risks associated with marketing our products and product candidates internationally could materially adversely affect our business.● ● ● ● 4 rw ▸ An active market for our shares of common stock may not continue to develop.● ● ● ● 4 rw ▸ Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects.● ● ● ● 4 rw ▸ Even after receiving any regulatory approval or introducing products or product candidates, we will continue to be subject to regulation of our manufacturing processes and advertising practices.● ● ● ● 4 rw ▸ Failure to obtain regulatory approval in foreign jurisdictions would prevent our products or product candidates from being marketed in those jurisdictions.● ● ● ● 4 rw ▸ If securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable research or other information about our business, our stock price and trading volume could decline.● ● ● ● 4 ▸ If we cannot successfully commercialize our products, especially ContraPest and Evolve, we will not become profitable.● ● ● ● 4 rw ▸ If we fail to obtain or protect intellectual property rights, our competitive position could be harmed.● ● ● ● 4 ▸ Intellectual property rights do not necessarily address all potential threats to any competitive advantage we may have.● ● ● ● 4 ▸ Our corporate documents, Delaware law and certain warrants contain provisions that could discourage, delay or prevent a change in control of our company.● ● ● ● 4 ▸ Our failure to accomplish any of these tasks could prevent us from successfully growing our business.● ● ● ● 4 ▸ Our success is dependent on the successful commercialization of ContraPest and Evolve.● ● ● ● 4 rw ▸ Our technology may be found to infringe third-party intellectual property rights.● ● ● ● 4 rw ▸ Privacy breaches and other cybersecurity risks related to our business and vulnerabilities through the use of evolving tools such as Artificial Intelligence could negatively affect our reputation, credibility, and business.● ● ● ● 4 rw ▸ Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.● ● ● ● 4 rw ▸ Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.● ● ● ● 4 ▸ group Risks Related to Our Intellectual Property and Legal Actions● ● ● ● 4 ▸ group Risks Related to Regulatory Matters● ● ● ● 4 ▸ group Risks Related to our Business● ● ● ● 4 ▸ group Risks Related to our Capital Stock, Funding, and Trading in our Stock● ● ● ● 4 rw ▸ group Risks Related to our Operations and Supply Chain● ● ● ● 4 ▸ group Risks Related to our Reporting and Cybersecurity● ● ● ● 4 ▸ The occurrence of any of the events described above would have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.● ● ● ● 4 ▸ These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.● ● ● ● 4 ▸ We have incurred significant operating losses every quarter since our inception and anticipate that we will continue to incur significant operating losses in the future.● ● ● ● 4 ▸ We may be subject to legal proceedings in the ordinary course of our business that could result in significant harm to our business, financial condition and operating results.● ● ● ● 4 ▸ We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.● ● ● ● 4 ▸ We may not be able to comply with all applicable listing requirements or standards of Nasdaq, and Nasdaq could delist our common stock.● ● ● ● 4 rw ▸ We will need to expand our operations and grow our organization, and we may experience difficulties in managing this growth.● ● ● ● 4 rw 
